After treatment, all drug-intervention groups showed a trend toward rebalancing CD4+ T cell subsets compared to the model group, with increased proportions of Th2 and Treg cells and reduced activation of Th1 and Th17 cells.
← all excerpts
Modified Guilu Erxian Glue regulates Treg immune function to suppress bone marrow failure in aplastic anemia mice.
1
—
—